Shawn Bishop (@Shawngbishop) published a blog post · October 1st, 2008
Crohn's Disease Study on Infliximab, Azathioprine
A study led by Mayo Clinic has found that infliximab (Remicade®) administered alone (monotherapy) or in combination with azathioprine is a more effective treatment for patients with moderate to severe Crohn’s disease than azathioprine alone. The findings were presented Oct. 6 at the 2008 American College of Gastroenterology (ACG) Annual Meeting.
Crohn’s disease is an inflammatory disorder of the gastrointestinal tract that affects an estimated 500,000 people in the United States. Symptoms include abdominal pain, fever, nausea, vomiting, weight loss and diarrhea. Crohn’s disease has no known medical cure.
“Historically, patients with Crohn’s disease have been treated sequentially with steroids, then azathioprine, then monoclonal antibodies such as infliximab. The study definitively demonstrates that infliximab-based strategies are more effective than azathioprine,” says William Sandborn, M.D., the lead author and a gastroenterologist at Mayo Clinic. “Clinicians should consider a shift in practice to incorporate this new data.”
The study, conducted at more than 130 sites, included 508 patients who have moderate to severe Crohn’s disease. Researchers found that 57 percent of patients who received combination therapy with infliximab and azathioprine achieved steroid-free remission after 26 weeks. This is compared to 44 percent of patients who achieved remission with infliximab monotherapy and 30 percent with azathioprine alone. Both the infliximab combination therapy and infliximab monotherapy groups were statistically superior to the azathioprine group. In addition, 61 percent of patients who received the combination therapy of infliximab and azathioprine also experienced healing of the bowel demonstrated by colonoscopy (mucosal healing).
Dr. William Sandborn, a Mayo Clinic gastroenterologist and the lead researcher on the study, provides background on the disease and describes the study purpose and findings below.